| Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma JJ Keats, R Fonseca, M Chesi, R Schop, A Baker, WJ Chng, S Van Wier, ... Cancer cell 12 (2), 131-144, 2007 | 1211 | 2007 |
| Genetic aberrations and survival in plasma cell leukemia RE Tiedemann, N Gonzalez-Paz, RA Kyle, R Santana-Davila, ... Leukemia 22 (5), 1044-1052, 2008 | 443 | 2008 |
| AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies M Chesi, DF Robbiani, M Sebag, WJ Chng, M Affer, R Tiedemann, ... Cancer cell 13 (2), 167-180, 2008 | 439 | 2008 |
| Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma C Leung-Hagesteijn, N Erdmann, G Cheung, JJ Keats, AK Stewart, ... Cancer cell 24 (3), 289-304, 2013 | 397 | 2013 |
| Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma S Trudel, ZH Li, J Rauw, RE Tiedemann, XY Wen, AK Stewart Blood, The Journal of the American Society of Hematology 109 (12), 5430-5438, 2007 | 267 | 2007 |
| Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma CB Reeder, DE Reece, V Kukreti, C Chen, S Trudel, K Laumann, J Hentz, ... Blood, The Journal of the American Society of Hematology 115 (16), 3416-3417, 2010 | 223 | 2010 |
| Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II. KR Hudson, RE Tiedemann, RG Urban, SC Lowe, JL Strominger, ... The Journal of experimental medicine 182 (3), 711-720, 1995 | 216 | 1995 |
| BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies JM Bogenberger, SM Kornblau, WE Pierceall, R Lena, D Chow, CX Shi, ... Leukemia 28 (8), 1657-1665, 2014 | 206 | 2014 |
| Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276 J Schmidt, E Braggio, KM Kortuem, JB Egan, YX Zhu, CS Xin, ... Leukemia 27 (12), 2357-2365, 2013 | 170 | 2013 |
| Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome RE Tiedemann, YX Zhu, J Schmidt, CX Shi, C Sereduk, H Yin, S Mousses, ... Cancer research 72 (3), 757-768, 2012 | 145 | 2012 |
| RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5 YX Zhu, R Tiedemann, CX Shi, H Yin, JE Schmidt, LA Bruins, JJ Keats, ... Blood, The Journal of the American Society of Hematology 117 (14), 3847-3857, 2011 | 132 | 2011 |
| Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6 RE Tiedemann, YX Zhu, J Schmidt, H Yin, CX Shi, Q Que, G Basu, ... Blood, The Journal of the American Society of Hematology 115 (8), 1594-1604, 2010 | 120 | 2010 |
| Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents CI Chen, E Masih‐Khan, H Jiang, A Rabea, C Cserti‐Gazdewich, ... British Journal of Haematology 162 (4), 483-488, 2013 | 116 | 2013 |
| Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation. RE Tiedemann, JD Fraser Journal of immunology (Baltimore, Md.: 1950) 157 (9), 3958-3966, 1996 | 114 | 1996 |
| Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-κB with antimyeloma activity in vitro and in vivo RE Tiedemann, J Schmidt, JJ Keats, CX Shi, YX Zhu, SE Palmer, X Mao, ... Blood, The Journal of the American Society of Hematology 113 (17), 4027-4037, 2009 | 112 | 2009 |
| The superantigen streptococcal pyrogenic exotoxin C (SPE-C) exhibits a novel mode of action PL Li, RE Tiedemann, SL Moffat, JD Fraser The Journal of experimental medicine 186 (3), 375-383, 1997 | 100 | 1997 |
| Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity RE Tiedemann, X Mao, CX Shi, YX Zhu, SE Palmer, M Sebag, R Marler, ... The Journal of clinical investigation 118 (5), 1750-1764, 2008 | 88 | 2008 |
| A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin X Mao, AK Stewart, R Hurren, A Datti, X Zhu, Y Zhu, C Shi, K Lee, ... Blood, The Journal of the American Society of Hematology 110 (12), 4047-4054, 2007 | 64 | 2007 |
| Patient-derived xenografts for prognostication and personalized treatment for head and neck squamous cell carcinoma C Karamboulas, JP Bruce, AJ Hope, J Meens, SH Huang, N Erdmann, ... Cell reports 25 (5), 1318-1331. e4, 2018 | 62 | 2018 |
| Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure R St Bernard, L Chodirker, E Masih-Khan, H Jiang, N Franke, V Kukreti, ... Bone marrow transplantation 50 (1), 95-99, 2015 | 60 | 2015 |
